Graham Wheeler
Titel
Citeras av
Citeras av
År
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 1-15, 2018
1492018
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
AL Ahern, GM Wheeler, P Aveyard, EJ Boyland, JCG Halford, AP Mander, ...
The Lancet 389 (10085), 2214-2225, 2017
1112017
Adaptive designs for dual-agent phase I dose-escalation studies
JA Harrington, GM Wheeler, MJ Sweeting, AP Mander, DI Jodrell
Nature Reviews Clinical Oncology 10 (5), 277, 2013
572013
How to design a dose-finding study using the continual reassessment method
GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ...
BMC medical research methodology 19 (1), 1-15, 2019
252019
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
G Wheeler, M Sweeting, A Mander
PLoS ONE 11 (7), e0159026, 2016
122016
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
GM Wheeler, MJ Sweeting, AP Mander
Statistics in Medicine 36 (16), 2499-2513, 2017
112017
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
G Wheeler
Statistical Papers, 1-11, 2016
72016
Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
GM Wheeler, MJ Sweeting, AP Mander, SM Lee, YKK Cheung
Statistics in medicine 36 (2), 225-241, 2017
52017
AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias Alves Pinto, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
42019
MA12. 05 phase 1 study of HSP90 inhibitor ganetespib with pemetrexed and cisplatin/carboplatin chemotherapy for pleural mesothelioma
D Fennell, S Danson, M Forster, D Talbot, P Woll, J Child, Y Ngai, ...
Journal of Thoracic Oncology 13 (10), S397, 2018
32018
The Lasso Logistic Regression Model: Modifications to aid causality assessment for Adverse Events Following Immunization
G Wheeler
London School of Hygiene and Tropical Medicine, 2010
32010
A review of available software for adaptive clinical trial design
MJ Grayling, GM Wheeler
Clinical Trials 17 (3), 323-331, 2020
22020
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
YNS Wong, P Sankey, DH Josephs, RJ Jones, SJ Crabb, S Beare, ...
Journal of Clinical Oncology 37 (15_suppl), TPS5090-TPS5090, 2019
22019
A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data
GM Wheeler, MJ Sweeting, AP Mander
Journal of the Royal Statistical Society: Series C (Applied Statistics) 68 …, 2019
22019
The effect of referral to an open‐group behavioural weight‐management programme on the relative risk of normoglycaemia, non‐diabetic hyperglycaemia and type 2 diabetes …
AL Ahern, SJ Griffin, GM Wheeler, SJ Sharp, P Aveyard, EJ Boyland, ...
Diabetes, Obesity and Metabolism 22 (11), 2069-2076, 2020
12020
Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
DA Fennell, S Danson, PJ Woll, M Forster, D Talbot, J Child, L Farrelly, ...
Clinical Cancer Research 26 (18), 4748-4755, 2020
12020
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app
P Pallmann, F Wan, AP Mander, GM Wheeler, C Yap, S Clive, ...
Clinical Trials 17 (2), 147-156, 2020
12020
Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and …
C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias Alves Pinto, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
12019
TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma.
A Davies, B Sage, K Kolluri, D Alrifai, R Graham, B Weil, R Rego, O Bain, ...
Journal of Clinical Oncology 37 (15_suppl), TPS9116-TPS9116, 2019
12019
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent …
MD Forster, JJ Sacco, AH Kong, G Wheeler, S Forsyth, R Bhat, K Blair, ...
Journal of Clinical Oncology 37 (15_suppl), TPS6091-TPS6091, 2019
12019
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20